UNI-BIO SCIENCE GROUP LIMITED

聯康生物科技集團有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 0690)

VOLUNTARY ANNOUNCEMENT

MARKETING APPLICATION OF ISAVUCONAZONIUM SULFATE CAPSULES HAS BEEN OFFICIALLY ACCEPTED BY THE CHINA NATIONAL MEDICAL PRODUCTS ADMINISTRATION (NMPA)

Hong Kong, 18 July 2025 — the board of directors (the "**Board**") of Uni-Bio Science Group Limited (the "**Company**", together with its subsidiaries, the "**Group**") in Hong Kong is pleased to announce that the China National Medical Products Administration (the "**NMPA**") has officially accepted the marketing application for **Isavuconazonium Sulfate Capsules**, under the acceptance number "CYHS2502599". This acceptance marks a significant milestone for the Group in the field of antifungal treatment. Isavuconazonium Sulfate Capsules are expected to be approved for launch in the second half of 2026. Providing patients suffering from invasive fungal infections, such as invasive aspergillosis and invasive mucormycosis, with a more effective, safer and high-quality treatment option.

Isavuconazonium Sulfate is a novel triazole antifungal agent with broad-spectrum antimicrobial activity. It works by inhibiting cytochrome P 450, disrupting ergosterol synthesis in fungal cell membranes, and weakening their structure and function. Clinical studies have confirmed its strong efficacy and high safety profile, offering a reliable treatment solution for patients suffering from life-threatening fungal infections.

The launch of Isavuconazonium Sulfate Capsules will create synergy with the existing product Pinup® (Voriconazole tablets), further solidifying the Group's leading position in the antifungal market. Pinup® has achieved sales coverage in public hospitals nationwide, and in order to enhance product accessibility and profitability, the Group is actively expanding its presence in the pharmacy network. Leveraging on the established sales network and a professional sales team for antifungal drugs, Isavuconazonium Sulfate Capsules will achieve efficient commercialized operation and maximize market penetration.

* *For identification purposes only*

In order to ensure the high-quality production and stable supply of Isavuconazonium Sulfate, the Group has **specifically modified a customized and dedicated production line** for this purpose. The production line is equipped with advanced capsule filling and aluminum-plastic packaging equipment, meets strict industry standards to ensure the precision and consistency of every batch of products. The cutting-edge technology required for the production of Isavuconazonium Sulfate Capsules is different from the technologies of other manufacturers, and has created a competitive advantage for the Group. In addition, the Group has established strategic cooperation relationships with high-quality API suppliers, ensuring a stable supply of high-quality raw materials and cost advantages, further solidifying its dual leading position in cost effectiveness and product quality.

The global antifungal drug market is expected to grow significantly, and China's market size is expected to reach approximately **RMB30 billion** by 2030, with a compound annual growth rate of over 10%. With Isavuconazonium Sulfate Capsules as a new generation of treatment option, the Group is well positioned to capture a considerable share in this rapidly expanding market.

Looking ahead, the launch of Isavuconazonium Sulfate Capsules will further enrich the Group's product pipeline, strengthen its leading position in the antifungal field, and contribute new momentum to sales growth. By adapting to the growing market demand for innovative and efficient therapies, the Group will continue to drive its firm commitment to biopharmaceutical innovation, providing value to patients and achieving sustainable growth for shareholders.

By Order of the Board
Uni-Bio Science Group Limited
Kingsley Leung
Chairman

Hong Kong, 18 July 2025